Deep within the bloodstream, the malaria parasite survives by repeating a quiet cycle of entering a red blood cell, multiplying, and moving on. Its first step, the docking of the merozoite onto the cell, has long been understood to depend on two protein families, EBA and Rh, whose members were thought to back one another up so that losing any single one changed little. A Nature study now shows that this backup is uneven rather than universal: when PfEBA175 is disabled alongside PfRh2b or PfRh4, the parasite's growth in cultured cells falls sharply. The finding hints that these few ligands may
Malaria Parasites Rely on a Core Trio of Invasion Ligands, Study Finds Redundancy Has Limits
The parasite's backups have limits
Mark
Why does it matter that these particular three proteins came out of the study?
Mimi
Because for a long time the story was that the parasite has backups. Knock out one invasion protein and others cover. This work shows the backups have limits when you remove EBA175 together with Rh2b or Rh4.
Mark
So it's about where the redundancy breaks.
Mimi
Yes. Some pairs of disruptions hurt invasion significantly and others don't, so the families aren't interchangeable.
Luke
Before we go further, what's actually been shown? Is this in patients?
Mimi
No. The reduced multiplication was measured in vitro, in cultured parasites.
Luke
Then the idea that these three are a critical nexus is the authors' interpretation, right?
Mimi
It's their reading, and they use the word 'may.' The data show reduced growth for those two pairings. The nexus label is how they explain it.
Mark
And the therapy angle?
Mimi
They say combination approaches targeting these ligands could be beneficial. That's a possibility, not a tested treatment.
Luke
Worth noting too that the source gives no numbers for how large the reduction was, only that it was significant. I can't tell you how much growth fell.
Il Polso
- The parasite has long slipped past attempts to block it because its invasion proteins seemed to cover for one another.
- Researchers disabled these invasion proteins in pairs, and one combination broke the parasite's ability to multiply.
- Disabling PfEBA175 with either PfRh2b or PfRh4 sharply reduced parasite growth in cultured red blood cells.
- The trio may form a critical core of the invasion machinery, opening a path toward combination treatments.
- Everything so far lives in the lab dish, and the idea of combination therapy has yet to be tested in people.
Deep within the bloodstream, the malaria parasite survives by repeating a quiet cycle of entering a red blood cell, multiplying, and moving on. Its first step, the docking of the merozoite onto the cell, has long been understood to depend on two protein families, EBA and Rh, whose members were thought to back one another up so that losing any single one changed little. A Nature study now shows that this backup is uneven rather than universal: when PfEBA175 is disabled alongside PfRh2b or PfRh4, the parasite's growth in cultured cells falls sharply. The finding hints that these few ligands may be the keystones of invasion, though it remains a laboratory result whose meaning for living patients is still to be discovered.
Inside the human bloodstream, the malaria parasite Plasmodium falciparum keeps itself alive by repeating one routine: it invades a red blood cell, multiplies inside it, and moves on. The first step, when the merozoite attaches to the cell, depends on two protein families, EBA and Rh. For a long time, researchers knew these proteins mattered, but they also knew that removing just one was not enough to stop invasion. The families seemed to hold spare capacity, so that when one member was lost, another could take over.
A new study published in Nature wanted to measure how far that backup really extends. Instead of disabling genes one at a time, the authors disrupted several EBA and Rh genes in combination, a systematic test of how these families depend on each other.
The redundancy turned out to be uneven. Some pairs, when disrupted, significantly impaired the parasite's ability to invade red blood cells, while others did not. The clearest effect came from disabling PfEBA175 together with either PfRh2b or PfRh4, which markedly reduced parasite multiplication in vitro. The authors concluded that the remaining proteins could not fully compensate for losing these three ligands.
From this, they suggest that PfEBA175, PfRh2b and PfRh4 may form a critical nexus of invasion, and that treatments aimed at these ligands in combination could prove useful. The work is clear about its limits: it was carried out in cultured cells, and the therapeutic idea remains a proposal. The open questions are whether this dependence holds outside the laboratory, and whether combination approaches can be turned into something usable against malaria.
Inside the human bloodstream, the malaria parasite Plasmodium falciparum stays alive by repeating one routine over and over: it invades a red blood cell, multiplies inside it, and moves on to the next. The first step in that routine, the moment the parasite's merozoite form attaches to the cell, depends on two families of proteins. One is the Erythrocyte binding-like family, known as EBA. The other is the Reticulocyte binding-like family, known as Rh.
Researchers have long known these proteins matter for invasion. They have also known that the parasite is hard to stop by removing just one. In laboratory culture, disrupting the function of a single EBA or Rh protein is not enough to prevent invasion. The families appear to contain a degree of redundancy, so that when one member is lost, others can carry the load.
A study published in Nature set out to test how far that redundancy actually goes. The authors used a new approach that lets them disrupt several EBA and Rh genes in combination, rather than one at a time. According to the paper, this is the first time functional interdependency across the two families has been assessed systematically.
The result is that the redundancy is uneven. Disrupting some pairs of EBA and Rh ligands significantly impairs the parasite's ability to invade red blood cells. Disrupting other pairs does not. In the authors' words, not all family members function equivalently.
The clearest effect involved a ligand called PfEBA175. When it was disrupted together with either PfRh2b or PfRh4, parasite multiplication in vitro dropped significantly. The authors read this to mean that the remaining EBA and Rh proteins cannot fully make up for the loss of these three key invasion ligands. The finding draws on further characterisation of the mutant parasites as well as the paired disruptions themselves.
From this, the authors propose that PfEBA175, PfRh2b and PfRh4 may form a critical nexus of the parasite's invasion machinery. If so, treatments that target these specific ligands in combination could be a useful therapeutic approach. The same logic cuts against hitting any one of them alone, since single disruptions are the very thing the parasite has been shown to withstand.
The limits of the work are plain in its own description. The experiments measured parasite multiplication in vitro, in cultured cells, and the therapeutic idea is framed as something that could be beneficial, not something yet tested. The next questions are whether the same dependence on this trio holds beyond the laboratory, and whether combination approaches aimed at these ligands can be built into anything usable against malaria.
Citazioni salienti
PfEBA175, PfRh2b and PfRh4 may represent a critical nexus of the parasite invasion machinery, and combinatorial approaches targeting them could be a beneficial therapeutic approach.— Study authors, Nature
Vuoi la storia completa?
Leggi l'originale su Nature ↗
Science & Space